Patent · US Active

Therapy-enhancing glucan

US9211304B2 · kind B2 · utility

2Cited by

53References

20Claims

0Family size

Assignees

Sloan Kettering Institute for Cancer Research · US
Biotec Pharmacon Asa · NO

Inventors

Nai-Kong V. Cheung · New York, US
Rolf Engstad · Tromsø, NO

Key dates

Filing date	Feb 6, 2013
Grant date	Dec 15, 2015
Priority date	—
Expiry date	Dec 1, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/55583
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.